Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ovid Therapeutics Inc. Director's Dealing 2021

Jun 12, 2021

34195_dirs_2021-06-11_b01c9509-5b3a-42a9-ac67-383334f05810.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ovid Therapeutics Inc. (OVID)
CIK: 0001636651
Period of Report: 2021-06-11

Reporting Person: Friedman Bart (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-11 Stock Option (Right to Buy) $4.49 A 15000 Acquired 2031-06-10 Common Stock (15000) Direct

Footnotes

F1: The option will vest in full on June 11, 2022 subject to the Reporting Person's continuous service through such vesting date.